August 2019 in “Journal of The American Academy of Dermatology” 5% minoxidil foam effectively regrows hair in women, with postmenopausal women seeing the most improvement.
153 citations,
January 2001 in “Science” Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.
66 citations,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
47 citations,
November 2012 in “Expert Opinion on Therapeutic Patents” The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.
40 citations,
December 2016 in “Journal of Dermatological Treatment” JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
37 citations,
August 2022 in “Frontiers in pharmacology” Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
32 citations,
September 2015 in “Dermatology” Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.
28 citations,
July 2017 in “Expert Review of Anticancer Therapy” Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
25 citations,
January 2021 in “Journal of drugs in dermatology” Sonidegib and vismodegib are similarly effective for advanced basal cell carcinoma, but sonidegib might have a slightly better safety profile.
20 citations,
January 2018 in “Expert opinion on emerging drugs” JAK inhibitors may soon be a safe and effective treatment for alopecia areata.
12 citations,
June 2023 in “JAMA network open” JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
9 citations,
February 2011 in “Biologics: Targets & Therapy” Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.
6 citations,
March 2016 in “Scandinavian journal of immunology” Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
6 citations,
April 2013 in “Current Dermatology Reports” Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.
4 citations,
April 2020 in “JAAD case reports” JAK inhibitors help hair regrowth but not fully effective for androgenetic alopecia.
4 citations,
January 2017 in “Biological & pharmaceutical bulletin” Inhibiting ALOX12 can help hair cuticle maturation by increasing S100A3 citrullination.
3 citations,
August 2013 in “Stem cells” Certain inhibitors applied to the skin can promote hair growth by maintaining a key hair growth signal.
1 citations,
April 2020 in “Journal of The European Academy of Dermatology and Venereology” Drugs like PDEI may help hair disorders like AGA.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
January 2024 in “Journal of Crohn's and colitis” Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
March 2018 in “Suez Canal University Medical Journal” New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.
May 2004 in “International Journal of Cosmetic Science” Melanogenesis inhibitors like kojic acid and niacinamide can reduce inflammation and pigment production in skin cells.
July 2003 in “Journal of Cutaneous Medicine and Surgery” The document concludes that various treatments for skin conditions are effective, but some require further research, and certain factors like gender and lifestyle can influence disease outcomes.
138 citations,
February 2007 in “European journal of cancer” EGFR inhibitors often cause skin problems and other side effects, but these are usually reversible and can be managed to keep patients comfortable.
116 citations,
February 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors help with skin conditions but need more research on dosing and safety.
87 citations,
December 2016 in “British journal of dermatology/British journal of dermatology, Supplement” Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.
41 citations,
November 1993 in “Journal of The American Academy of Dermatology” DPCP helps treat severe hair loss, but 5% minoxidil doesn't add benefits.
18 citations,
January 2017 in “Postępy Dermatologii i Alergologii” EGFR inhibitors can cause various skin issues during cancer treatment, and managing these is important for patient care.
18 citations,
July 2008 in “Current Oncology Reports” EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
17 citations,
December 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists found new, better-working inhibitors for a hormone-related enzyme.